Summit Therapeutics (SMMT) Enterprise Value (2018 - 2026)

Summit Therapeutics has reported Enterprise Value for 9 years, with the latest figure at -$106.8 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 49.57% year-over-year to -$106.8 million; the trailing twelve-month figure through Mar 2026 stood at -$106.8 million (up 49.57% YoY), and the FY2025 full-year result was -$225.6 million, up 45.29% from the prior year.
• Enterprise Value for Q1 2026 stood at -$106.8 million, up from -$225.6 million in the prior quarter.
• The five-year high for Enterprise Value was -$23.8 million in Q3 2023, with the low at -$648.6 million in Q4 2022.
• Historically, Enterprise Value has averaged -$200.0 million across 5 years, with a median of -$211.8 million in 2025.
• Annual changes were most pronounced in 2023 — Enterprise Value jumped 88.99% — and 2025, when it sank 935.93%.
• Summit Therapeutics' Enterprise Value stood at -$648.6 million in 2022, then jumped by 88.99% to -$71.4 million in 2023, then plunged by 477.32% to -$412.3 million in 2024, then jumped by 45.29% to -$225.6 million in 2025, then surged by 52.64% to -$106.8 million in 2026.
• The last three Enterprise Value figures came in at -$106.8 million (Q1 2026), -$225.6 million (Q4 2025), and -$238.9 million (Q3 2025), per Business Quant data.